CPRX - Catalyst Pharmaceuticals, Inc.
2.89 0.00 (0.00%)
After hours: 4:59PM EDT
| Previous Close | 2.64 |
| Open | 2.64 |
| Bid | 2.90 x 400 |
| Ask | 2.98 x 5000 |
| Day's Range | 2.61 - 2.95 |
| 52 Week Range | 1.64 - 4.51 |
| Volume | 2,088,709 |
| Avg. Volume | 679,583 |
| Market Cap | 296.387M |
| Beta | 2.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.22 |
| Earnings Date | May 8, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.25 |
- GlobeNewswire•6 days ago
Report: Developing Opportunities within Clean Energy Fuels, Catalyst Pharmaceuticals, Qorvo, Brunswick, DCT Industrial Trust, and Radius Health — Future Expectations, Projections Moving into 2018
NEW YORK, April 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•7 days ago
Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Trial of Firdapse® in MuSK Antibody Positive Myasthenia Gravis
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the first patient has been enrolled into its Phase 3 clinical trial (designated as MSK-002) to evaluate the efficacy and safety of Firdapse® (amifampridine phosphate) in patients with MuSK antibody positive Myasthenia Gravis (MuSK-MG).
- American City Business Journals•28 days ago
Catalyst Pharmaceuticals files new drug application with FDA
The Coral Gables-based company is another step closer to bringing a new drug to market.
- GlobeNewswire•28 days ago
Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse® for Treatment of Lambert-Eaton Myasthenic Syndrome
CORAL GABLES, Fla., March 29, 2018-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic ...
- Associated Press•last month
Catalyst reports 4Q loss
On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 6 cents. The results matched Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- GlobeNewswire•last month
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
--Firdapse ® NDA to be Resubmitted Before the End of this Quarter. --Significant Progress with MuSK-MG Regulatory and Clinical Program. --$84 M Year-End Cash and Investments.
- Insider Monkey•last month
Catalyst Pharmaceuticals Inc (CPRX) and Achillion Pharmaceuticals, Inc. (ACHN) Among Five Cheap Healthcare Stocks To Buy Now
There are plenty of opportunities to invest in healthcare stocks, as there are thousands of companies, ranging from big and well-established pharmaceuticals that also pay substantial dividends, to small, emerging companies without any products on the market or revenue, but backed by their research into novelty therapies for various illnesses. When looking for healthcare stocks […]
- Simply Wall St.•last month
When Will Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Breakeven?
Catalyst Pharmaceuticals Inc’s (NASDAQ:CPRX): Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. With the latest financial year lossRead More...
- GlobeNewswire•last month
Catalyst Pharmaceuticals Announces Date and Time Change for Fourth Quarter and Year-End Financial Results Call and Webcast
CORAL GABLES, Fla., March 12, 2018-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic ...
- GlobeNewswire•2 months ago
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results Conference Call and Webcast on Thursday, March 15th, 2018
CORAL GABLES, Fla., March 08, 2018-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic ...
- Zacks•2 months ago
What's in Store for Catalyst (CPRX) This Earnings Season?
Investors focus will be on pipeline and regulatory updates during Catalyst's (CPRX) fourth-quarter earnings call.
- GlobeNewswire•2 months ago
Catalyst Pharmaceuticals Announces Its Continuing Support for Rare Disease Day 2018
CORAL GABLES, Fla., Feb. 28, 2018-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic ...
- GlobeNewswire•2 months ago
Detailed Research: Economic Perspectives on Carbo Ceramics, Consolidated Communications, Catalyst Pharmaceuticals, Office Depot, ImmunoGen, and Cedar Realty Trust — What Drives Growth in Today's Competitive Landscape
NEW YORK, Feb. 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Carbo ...
- GlobeNewswire•2 months ago
Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse®
Positive meeting with the FDA about the resubmission of an NDA for Firdapse Resubmission of NDA for Firdapse on schedule for end of the first quarter. CORAL GABLES, Fla., Feb. 12, 2018-- Catalyst Pharmaceuticals, ...
- GlobeNewswire•3 months ago
Catalyst Pharmaceuticals to Present at Two Upcoming Investor Conferences
CORAL GABLES, Fla., Feb. 07, 2018-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic ...
- Motley Fool•5 months ago
3 Drug Stocks That Soared This Week: Are They Buys?
Can Catalyst, Sucampo, and Peregrine keep the momentum going?
- Marketwired•5 months ago
Catalyst Pharmaceuticals, Inc. Prices Previously Announced Public Offering of Common Stock
Catalyst Pharmaceuticals, Inc. today announced the pricing of its previously announced underwritten public offering. The Company announced that it is selling 14,285,715 shares of its common stock in the ...
- Associated Press•6 months ago
Catalyst reports 3Q loss
The Coral Gables, Florida-based company said it had a loss of 5 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Simply Wall St.•6 months ago
Have Investors Already Priced In Catalyst Pharmaceuticals Inc’s (CPRX) Growth?
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), a biotechnology company based in United States, led the NasdaqCM gainers with a relatively large price hike in the past couple of weeks. With many analystsRead More...
